Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 9/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 8/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 5/20 | 0.34 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16121733 | 0.89 | CARM1 (0.39) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| Trifluoroacetic Acid SCHEMBL30014474 | 0.88 | PRMT1 (0.42) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187080 | 0.84 | CARM1 (0.41) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| Trifluoroacetic Acid SCHEMBL30015624 | 0.84 | PRCP (0.35) | PRMT6 | |
| Trifluoroacetic Acid SCHEMBL16099966 | 0.80 | PRMT1 (0.36) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187091 | 0.79 | CARM1 (0.42) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187094 | 0.79 | CARM1 (0.45) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187088 | 0.78 | CARM1 (0.47) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187103 | 0.78 | HTR1D (0.30) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| Trifluoroacetic Acid SCHEMBL16178113 | 0.76 | TRPV1 (0.32) | RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11512053-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512053-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | CARM1 11/4885PRMT1 1/4885PRMT6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.